3 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 9 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Unknown 3, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 4 | Unknown 3, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Decitabine (DAC): new trials by email Literature Review of Decitabine (DAC) trials Research Report on Decitabine (DAC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 232 | 2022-07-01 | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2022-07-01 | 2023-03-21 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2021-01-15 | 2021-01-19 |
| Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2018-04-11 | 2023-05-31 |
| Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy decitabine (DAC), Tetrahydrouridine (THU), Celecoxib - Neoplasm Metastasis, Sarcoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-07-07 | 2018-07-05 | |
| Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC) - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 185 | 2014-10-13 | 2025-08-07 |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, fludarabine phosphate, busulfan - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | University of Wisconsin, Madison | 20 | 2013-05-16 | 2019-11-21 |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Filgrastim, Busulfan, Cyclophosphamide - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 1995-08-01 | 2018-10-26 |
Leukemia (3) · Myelodysplastic Syndromes (3) · Leukemia, Myeloid, Acute (2) · Blast Crisis (1) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Abnormalities (1) · Esophageal Neoplasms (1) · Leukemia, Myeloid, Accelerated Phase (1) · Lung Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1) · Neoplasms, Germ Cell and Embryonal (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Nanfang Hospital, Southern Medical University (4) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · University of Wisconsin, Madison (1)
China (4) · United States (4)
Qifa Liu (3) · David S Schrump, M.D. (2) · Guillermo Garcia-Manero (1) · Mark Juckett (1) · Sergio Giralt, MD (1)
P30CA014520 (1), P30CA016672 (1)